Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2007). Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis..
Metab Syndr Relat Disord. 8(6), 523-9.
(2010). Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome..
Angiology. 61(1), 49-57.
(2010). Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?.
Atherosclerosis. 211(1), 9-14.
(2010). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors..
Hormones (Athens). 15(1), 8-14.
(2016). Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007). Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, ea.
J Hypertens. 36(7), 1441-1455.
(2018). Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension.
J Hypertens. 36(7), 1427-1440.
(2018). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study..
Arch Med Sci. 7(5), 796-805.
(2011). Should atenolol still be recommended as first-line therapy for primary hypertension?.
Hellenic J Cardiol. 47(5), 298-307.
(2006). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005).